Enterprise Value
-46.06M
Cash
118.7M
Avg Qtr Burn
-11.98M
Short % of Float
0.07%
Insider Ownership
41.27%
Institutional Own.
46.39%
Qtr Updated
12/31/23
Drug Pipeline
Powered by
![](/BPIQ_Pill.png)
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Rademikibart (CBP-201) (Th2 cell modulator) Details Atopic dermatitis | NDA Submission | |
Phase 2b Update | ||
Phase 2 Update | ||
CBP-174 (Peripherally restricted H3 receptor antagonist) Details Chronic pruritus | Phase 1 Update | |
Failed Discontinued | ||
Rademikibart (CBP-201) (Th2 cell modulator) Details Chronic rhinosinusitis, Chronic rhinosinusitis with nasal polyps | Failed Discontinued |